Biotechnology company Odyssey Therapeutics applies for listing in the U.S. and plans to raise $100 million
Biotechnology company Odyssey Therapeutics submitted its initial public offering (IPO) application to the U.S. Securities and Exchange Commission (SEC) last Friday, planning to raise $100 million. The company plans to list on NASDAQ under the ticker symbol "ODTX." Odyssey Therapeutics focuses on patients with autoimmune and inflammatory diseases and is developing drugs aimed at precisely targeting disease pathology. Its leading candidate drug, OD-07656, is a small molecule scaffold inhibitor of receptor interacting protein kinase 2. The company plans to begin a Phase 2a monotherapy trial for ulcerative colitis in the first quarter of 2025 and a Phase 2a combination therapy trial with Vedolizumab in the first half of 2026. The company's product line also includes two preclinical projects: a small molecule scaffold inhibitor of interleukin-1 receptor-associated kinase 4 and an agonist protein therapy targeting tumor necrosis factor receptor 2. The company, headquartered in Boston, Massachusetts, was founded in 2021. For the 12 months ending September 30, 2024, the company's collaboration revenue was $3 million
According to Zhitong Finance APP, biotechnology company Odyssey Therapeutics submitted its initial public offering (IPO) application to the U.S. Securities and Exchange Commission (SEC) last Friday, planning to raise $100 million. The company plans to list on NASDAQ under the ticker symbol "ODTX."
Odyssey Therapeutics focuses on patients with autoimmune diseases and inflammatory diseases, developing drugs aimed at precisely targeting disease pathology. Its leading candidate drug, OD-07656, is a small molecule scaffold inhibitor of receptor interacting protein kinase 2. The company plans to begin a Phase 2a monotherapy trial for ulcerative colitis in the first quarter of 2025 and a Phase 2a combination therapy trial with Vedolizumab in the first half of 2026. The company's product line also includes two preclinical projects: a small molecule scaffold inhibitor of interleukin-1 receptor-associated kinase 4 and an agonist therapy targeting tumor necrosis factor receptor 2.
The company, headquartered in Boston, Massachusetts, was founded in 2021. For the 12 months ending September 30, 2024, the company's collaboration revenue was $3 million
